Skip to main content
. 2022 Nov 19;23:316. doi: 10.1186/s12931-022-02240-1

Fig. 5.

Fig. 5

The pharmacokinetic and pharmacodynamic effects of the trivalent IL-5-HSA Nb in cynomolgus monkeys. A Schematic representation of its pharmacokinetic and pharmacodynamic study. B The pharmacokinetic effect of the trivalent IL-5-HSA Nb in cynomolgus monkeys with the primary doses of 5 mg/kg and 2 mg/kg. The plasma concentration of trivalent IL-5-HSA Nb was measured within 56 days. C The inhibitory effect of the trivalent IL-5-HSA Nb on eosinophil (EOS) numbers was determined within 84 days